Cerulean Pharma Raises $10 Million
Cerulean Pharma Inc. , a Cambridge, Mass.-based developer of nanoparticle-based drugs, has raised $10 million in Series B-1 funding. Return backers include Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners. The company had previously raised around $20 million, and last month signed a worldwide licensing agreement for a drug delivery technology and clinical-stage oncology product candidate developed by Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corp. (Nasdaq: ARWR).
28 July 2009•3 mins read
